ARTICLE | Clinical News
IdeS: Ph II discontinued
January 27, 2017 4:35 AM UTC
Hansa discontinued an open-label, U.K. Phase II trial evaluating a single IV dose of IdeS after preliminary data from 2 asymptomatic patients with acquired TTP showed a "non-favorable" risk-benefit pr...
BCIQ Company Profiles
BCIQ Target Profiles